{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:13:12Z","timestamp":1648649592636},"reference-count":19,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.vaccine.2015.10.126","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T12:22:20Z","timestamp":1446812540000},"page":"7203-7210","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey"],"prefix":"10.1016","volume":"33","author":[{"given":"Merryn","family":"Voysey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahele","family":"Tavana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yama","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Bonhoeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.10.126_bib0100","series-title":"Recommended for adoption at step","first-page":"4","article-title":"Clinical safety data management: definitions and standards for expedited reporting","author":"ICH Harmonized Tripartite Guideline","year":"1994"},{"key":"10.1016\/j.vaccine.2015.10.126_bib0105","series-title":"Assessment report\u2014Bexsero","author":"European Medicines Agency","year":"2012"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.126_bib0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0253-7613.125192","article-title":"A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions","volume":"46","author":"Belhekar","year":"2014","journal-title":"Indian J Pharmacol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.126_bib0115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4067\/S0034-98872015000700009","article-title":"Comparison of two methods to assess causality of adverse drug reactions","volume":"143","author":"Kyonen","year":"2015","journal-title":"Rev Med Chil"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.126_bib0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2710.2003.00475.x","article-title":"Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability","volume":"28","author":"Macedo","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.vaccine.2015.10.126_bib0125","unstructured":"Brighton Collaboration. https:\/\/brightoncollaboration.org\/public. Accessed 7th Nov 2015."},{"key":"10.1016\/j.vaccine.2015.10.126_bib0130","unstructured":"United Kingdom Paediatric Vaccine Group (UKPVG). http:\/\/ukpvg.org\/ukpvg\/internet\/en\/index.html. Accessed 7th November 2015."},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.126_bib0135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.126_bib0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.126_bib0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1473-3099(11)70100-1","article-title":"Safety and efficacy of the RTS, S\/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial","volume":"11","author":"Asante","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.126_bib0150","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/CVI.00062-10","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers","volume":"17","author":"Esposito","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.126_bib0155","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"44","key":"10.1016\/j.vaccine.2015.10.126_bib0160","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2015.10.126_bib0165","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.126_bib0170","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Moher","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.126_bib0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.126_bib0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/QCO.0b013e3283607a58","article-title":"Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants","volume":"26","author":"Lindsey","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.126_bib0185","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/archdischild-2013-305716","article-title":"Attitudes towards vaccination against group B streptococcus in pregnancy","volume":"99","author":"McQuaid","year":"2014","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2015.10.126_bib0190","unstructured":"Information available at ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/search\/map. Accessed 1st September 2015."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T11:14:19Z","timestamp":1556363659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15015820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":19,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0264410X15015820"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.126","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}